Cardio Diagnostics Holdings (CDIO) EBT Margin (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted EBT Margin of 66722.31% for Q1 2026, down 61.87% sequentially from 41219.92% in Q4 2025, and up 10722067.0% YoY from N/an in Q1 2025.
Cardio Diagnostics Holdings (CDIO) EBT Margin (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported EBT Margin for 5 years, with the latest figure at 66722.31% in Q1 2026.
- Quarterly EBT Margin rose 10722067.0% year-over-year to 66722.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40152.5% (down 1073368.0% YoY) and the FY2025 annual result came in at 43832.49%, down 1980425.0% from the prior year.
- EBT Margin fell to 66722.31% in Q1 2026 per CDIO's latest filing, from 41219.92% in the prior quarter.
- Over five years, EBT Margin peaked at 16365.88% in Q2 2024 and troughed at 250321.79% in Q4 2022.
- A 5-year average of 76235.34% and a median of 33672.61% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2025: EBT Margin surged 22416493 bps in 2023, then plunged 14780295 bps in 2025.
- Over 5 years, EBT Margin stood at 250321.79% in 2022, then soared by 90 bps to 26156.85% in 2023, then fell by 29 bps to 33672.61% in 2024, then slipped by 22 bps to 41219.92% in 2025, then tumbled by 62 bps to 66722.31% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 66722.31%, 41219.92%, and 60053.8% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 12.09% |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | -28,012.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28,012.46% |
| Mar 31, 2026 | -66,722.31% |
| Dec 31, 2025 | -41,219.92% |
| Sep 30, 2025 | -60,053.80% |
| Jun 30, 2025 | -22,517.71% |
| Mar 31, 2025 | -173,942.98% |
| Dec 31, 2024 | -33,672.61% |
| Sep 30, 2024 | -21,467.57% |
| Jun 30, 2024 | -16,365.88% |
| Mar 31, 2024 | -26,140.03% |
| Dec 31, 2023 | -26,156.85% |
| Sep 30, 2023 | -19,266.02% |
| Jun 30, 2023 | -233,211.88% |
| Dec 31, 2022 | -250,321.79% |